Aveo Pharmaceuticals Next Hit ?
| eröffnet am: | 10.06.14 20:27 von: | MasterbrokerUSA |
| neuester Beitrag: | 25.04.21 03:03 von: | Lisauefea |
| Anzahl Beiträge: | 336 | |
| Leser gesamt: | 143348 | |
| davon Heute: | 43 | |
bewertet mit 4 Sternen |
||
|
|
||
Erst ab dem 20.06. kann AVEO so richtig fliegen, dann gibt es wohl keinen Call mehr mit Basis 2,50.
Hat da jemand eine Meinung zum Zusammenhang zwischen den Optionen und dem Kurs?
aveo_optionen.png (verkleinert auf 49%)
...
Zeitpunkt: 01.07.15 10:12
Aktion: Nutzer-Sperre für immer
Kommentar: Doppel-ID - Von: teke
AVEO Announces Exclusive Worldwide License Agreement for the Development and Commercialization of AV-380 and Related Antibodies
Business Wire AVEO Oncology
4 hours ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
AVEO Oncology (AVEO) today announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody (the “Product”).
Under the terms of the agreement, AVEO will receive an upfront payment of $15 million and will be eligible to receive reimbursement, clinical, sales and regulatory-based milestone payments totaling $311 million assuming successful advancement of the Product. AVEO will also be eligible to receive tiered royalties on product sales ranging from high single digits to a low double-digit. Novartis will be responsible for all clinical development, manufacturing and commercialization activities and costs associated with the Product.
“AV-380 holds great promise as a potential treatment for cachexia secondary to multiple disease states, including cancer, chronic kidney disease, congestive heart failure and chronic obstructive pulmonary disease,” said Michael Bailey, AVEO’s president and chief executive officer. “Novartis brings resources and expertise to bear on advancing this program, which we believe provides the optimal path forward toward realizing its full potential.”
https://clinicaltrials.gov/ct2/show/...amp;rank=4&submit_fld_opt=
mit Beginn im Januar gelistet:
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
http://www.nasdaq.com/press-release/...zanib-in-europe-20151221-00147
https://clinicaltrials.gov/ct2/show/results/...3?term=Aveo&rank=1
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
CEO, CMO & CFO erwirbt 460.000 Aktien, 184.000 Aktien bzw. 149.500 Aktien zu jeweils 1,08 $.
http://investor.aveooncology.com/...?c=219651&p=irol-sec#14272273
Was wird hier verhandelt?
-0,11 $ statt der erwarteten -0,14 $ im Q4 2015
http://www.nasdaq.com/article/...imates-in-q4-earnings-again-cm587588
aveo.png (verkleinert auf 51%)
Zeitpunkt: 15.03.16 12:31
Aktion: Löschung des Beitrages
Kommentar: Moderation auf Wunsch des Verfassers
http://www.nasdaq.com/article/...expected-tivozanib-in-focus-cm593890
...AVEO's performance in the fourth quarter was impressive with the company reporting a narrower-than-expected loss. The company's focus on exploring partnerships for the development of tivozanib is encouraging. We expect to see agreements related to tivozanib in the near term. However, uncertainties on the outcome of its discussions with the SEC remain a major overhang on the stock...
bzgl. Informationszurückhaltung gegenüber den Aktionären:
http://www.sec.gov/news/pressrelease/2016-59.html
Seite 14
http://www.ema.europa.eu/docs/en_GB/...Agenda/2016/07/WC500210596.pdf
tivozanib.png (verkleinert auf 21%)
http://sleekmoney.com/...nc-aveo-rating-reiterated-by-fbr-co/1448455/
AVEO Pharmaceuticals Inc. (NASDAQ:AVEO)s stock had its buy rating reissued by research analysts at FBR & Co in a research report issued on Monday.
AVEO has been the topic of a number of other reports. Zacks Investment Research raised AVEO Pharmaceuticals from a hold rating to a buy rating and set a $1.00 target price on the stock in a report on Monday, April 18th. Piper Jaffray Cos. started coverage on AVEO Pharmaceuticals in a report on Thursday, May 19th. They set an overweight rating and a $1.70 target price on the stock.
AVEO Pharmaceuticals (NASDAQ:AVEO) traded down 4.0629% during mid-day trading on Monday, reaching $0.9209. 283,410 shares of the company were exchanged. AVEO Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $2.59. The stocks 50-day moving average is $0.97 and its 200-day moving average is $0.97. The companys market cap is $53.58 million.
An institutional investor recently raised its position in AVEO Pharmaceuticals stock. Renaissance Technologies LLC increased its position in shares of AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) by 6.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,094,900 shares of the biopharmaceutical companys stock after buying an additional 119,000 shares during the period. Renaissance Technologies LLC owned 3.60% of AVEO Pharmaceuticals worth $1,927,000 at the end of the most recent quarter.
AVEO Pharmaceuticals, Inc (AVEO) is a biopharmaceutical company. The Companys platform has delivered insights into cancer and related disease. The Companys Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates.
Im letzten Quartal ist ein neuer Investro mit über 10 Millionen Aktien eingestiegen:
http://www.nasdaq.com/symbol/aveo/institutional-holdings
aveo.png (verkleinert auf 31%)
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibbs Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma
http://investor.aveooncology.com/...p=irol-newsArticle&ID=2195320
Aveo today announced discontinuation of the FOCAL study...
http://secfilings.nasdaq.com/...%20INC&FormType=8-K&View=html